Physician profile
Satwinder Singh
NPI 1295770709
$2,293.96
in general payments reported to CMS, 2019-2025
15 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $290 · 2021: $355 · 2022: $344 · 2023: $255 · 2024: $217 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.47 | 2021-2025 | Avycaz |
| Viiv Healthcare Company | $440.05 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $355.76 | 2019-2025 | Biktarvy |
| Allergan, INC. | $316.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $293.79 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Astellas Pharma US INC | $56.50 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $53.38 | 2023 | Xerava |
| Smith+Nephew, INC. | $43.59 | 2020-2022 | |
| Janssen Biotech, INC. | $41.71 | 2022-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.32 | 2025 | Rebyota |
| Shionogi INC | $14.54 | 2023 | Fetroja |
| Theratechnologies INC. | $14.07 | 2019 | |
| Pfizer INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satwinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.